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Background: Recently, recurrent point mutations in the telomerase reverse transcriptase (TERT) promoter region
have been found in many human cancers, leading to a new transcription factor binding site, increased induction of
TERT and subsequently to telomere maintenance. We determined the prevalence of TERT promoter mutations in
soft tissue sarcomas of 341 patients comprising 16 entities and in 16 sarcoma cell lines covering 7 different soft
tissue sarcoma types.
Methods: The sarcoma tissue samples were collected from the archives of the Institute of Pathology, University of
Heidelberg and were composed of 39 myxoid liposarcomas (MLS), 61 dedifferentiated liposarcomas, 15 pleomorphic
liposarcomas, 27 leiomyosarcomas, 25 synovial sarcomas (SS), 35 malignant peripheral nerve sheath tumors (MPNST),
40 undifferentiated pleomorphic sarcomas, 17 myxofibrosarcomas, 9 low grade fibromyxoid sarcomas, 10 cases of
dermatofibrosarcoma protuberans, 31 solitary fibrous tumors (SFT), 8 extraskeletal myxoid chondrosarcomas, 9
angiosarcomas, 6 alveolar soft part sarcomas, 5 clear cell sarcomas and 4 epithelioid sarcomas. Sarcoma cell lines
were obtained from the raising laboratories. A 193 bp fragment of the TERT promoter region covering the hot-spot
mutations C228T and C250T was amplified, and direct sequencing of the PCR products was performed.
Results: TERT promoter mutations were detected in 36/341 sarcomas. They were highly recurrent in MLS (29/39; 74%)
and were in the present MLS series not associated with the phenotype (myxoid vs. round cell variant), tumor grade,
tumor site and patients’ median age or gender. In the remaining cases, TERT promoter mutations were found only
in 7/302 sarcoma samples and confined to SFTs (4/31; 13%), MPNSTs (2/35; 6%), and SSs (1/25; 4%). Within the
collection of sarcoma cell lines examined, TERT promoter mutations were detected in two MLS and in one of three
MPNST cell lines.
Conclusions: TERT promoter mutations are frequent in MLSs including their round cell variants, representing the
most prevalent mutation identified in this sarcoma entity to date, and in a minor fraction of SFTs, MPNSTs and
SSs. The majority of sarcomas are devoid of TERT promoter hotspot mutations. These data suggest that telomere
maintenance through increased expression of telomerase plays an important role in the pathogenesis especially
of MLS.
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Soft tissue sarcomas (STS) are a highly heterogeneous
group of malignant tumors of mesenchymal origin rep-
resented by voluntary muscles, fat, and fibrous tissue
and their vessels and by convention the peripheral ner-
vous system [1]. STS are relatively rare and constitute
approximately 1–2% of all human cancers, but incidence
dramatically increases with age [1,2].
Since most patients with STS present with a painless
swelling, a delayed diagnosis is common, often with local
or distant metastatic spread at the time of diagnosis [2].
The treatment of choice depends on the individual
tumor type, grading and staging status. Surgery, among
others, is a key element of therapy in sarcomas of adults
with the aim of microscopically tumor-negative margins
for optimal local control [3]. However, standardized
treatment might be insufficient. Under these circum-
stances, advance in personalized treatment strategies
might become important with the goal to individual
tumor-targeted therapies.
That is why the biology of STS has intensively been in-
vestigated over the last decades with a dramatic increase
of knowledge about genetic alterations [4] including ab-
errant DNA methylation [5]. In general, sarcomas can
be classified into two genetic groups: i. sarcomas with
specific chromosomal rearrangements on a background
of relatively few other chromosomal changes, and ii. sar-
comas without specific alterations on a complex back-
ground of numerous chromosomal changes [6]. Specific
genetic alterations are not only of diagnostic signifi-
cance, but also might become relevant for tumor-targeted
therapies.
Telomere maintenance is an important step during
tumorigenesis and confers unlimited proliferative cap-
acity to cancer cells [7]. In principal, two mechanisms
can be involved in telomere maintenance: a telomerase
dependent mechanism or a non-telomerase dependent
mechanism also referred to as Alternative Lengthening
of Telomeres (ALT) [7]. The ribonucleoprotein complex
telomerase provides the physiological mechanism that
maintains telomere length by adding repetitive hexanu-
cleotide repeats with the sequence 5′-TTAGGG-3′ to
telomeres. Reactivation of telomerase has been observed
in the majority of human cancers [8]. In this context,
telomerase reverse transcriptase (TERT) serves as the
catalytic subunit of the telomerase complex and has
been shown to contribute to the immortalization of can-
cer cells [7]. However, the underlying mechanism of
TERT reactivation in cancer cells was an unresolved
issue [9].
Recently, highly recurrent somatic mutations in the
promoter region of the TERT gene have been detected
[10]. The most frequent mutations were a single cytosine
exchange to thymine at chromosome 5 base position1,295,228 (C228T) or less frequently at base position
1,295,250 (C250T) (−124 and −146 bp from ATG start
site, respectively). These TERT mutations lead to a new
binding motif for E-twenty six/ternary complex factors
(Ets/TCF) transcription factors and results in an up to
4-fold increase of TERT promoter activity in reporter
gene assays [11,12].
First described in melanomas [11,12], TERT promoter
mutations have subsequently been found in many other
human cancer types, with highest frequencies in sub-
types of CNS tumors, in a number of malignancies of
epithelial origin including bladder carcinomas, thyroid
carcinomas, and hepatocellular carcinomas, and in atyp-
ical fibroxanthomas and in dermal pleomorphic sarco-
mas [13-26]. Accordingly, TERT promoter mutations
belong to the most common somatic genetic lesions in
human cancers.
A study by Killela et al. investigated a broad range of
human cancers for TERT promoter mutations, including
soft tissue sarcomas [16]. However, the case number of
single STS entities was limited and a number of subtypes
were not comprised.
Therefore, the present study was conducted to investi-
gate the prevalence of TERT promoter mutations in a
comprehensive series of 341 soft tissue tumors com-
prised of 16 types including rare entities and in 16 cell
lines of seven sarcoma types. Further, we looked for as-
sociations, if any, with clinicopathological parameters.
Materials and methods
Sarcoma samples and clinicopathological characteristics
The sarcoma tissue samples were collected at the Insti-
tute of Pathology, University of Heidelberg, and diag-
noses were confirmed by three sarcoma pathologists
(GM, WH and EW). Diagnoses were based on standard
histopathological criteria in conjunction with immu-
nohistological and molecular analysis according to the
current WHO classification of tumors [1]. Only sam-
ples with at least 80% vital tumor cells were selected
for the analysis. The study was approved by the ethics
committee, medical faculty of heidelberg University
(No. 206/2005, 207/2005). The clinicopathological charac-
teristics are shown in Additional file 1: Table S1. Further
molecular and histological data of myxoid liposarcomas
are given in Additional file 1: Table S2. The sarcoma cell
lines examined, together with references, molecular con-
firmation and culture conditions are detailed in Additional
file 1: Table S3 (according to reference [5]).
DNA isolation
DNA was extracted from 1 to 3 (depending on the
size of the tumor sample) 8 μm thick sections from
formalin-fixed and paraffin embedded (FFPE) samples
using the Maxwell® 16 FFPE Tissue LEV DNA Purification
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turer’s instructions. The extracted DNA was quantified
with the Nanodrop ND-1000 spectrophotometer (Nano-
Drop Technologies, Rockland, USA).
Direct (Sanger) sequencing
A 193 bp fragment of the TERT promoter region span-
ning the hotspot mutations at positions 1,295,228 and
1,295,250 on chromosome 5 was amplified by using
GoTaq G2 Hot Start Polymerase (Promega, Madison,
USA) and the following primers: hTERT-seq-for 5′-
CACCCGTCCTGCCCCTTCACCTT-3′ and hTERT-seq-
rev 5′- GGCTTCCCACGTGCGCAGCAGGA-3′. PCR
was performed with 100 ng of DNA template in a total
volume of 25 μl, and included initial denaturation at 95°C
for 120 s, followed by 35 cycles with denaturation at
95°C for 30 s, annealing at 68°C for 30 s, and extension
at 72°C for 40 s. In cases where amplification of the large
fragment failed, primers hTERT-short-for 5′-CAGCGC
TGCCTGAAACTC-3′ and hTERT-short-rev, 5′-GTC
CTGCCCCTTCACCTT-3′, which amplify a 163 bp
fragment, were applied as described previously [17].
PCR products were purified using USB Exo-SAP-IT
(Affymetrix, Cleveland, USA) and direct sequencing of
the PCR products was performed for both strands on an
ABI 3500 genetic analyzer (Life Technologies, Darmstadt,
Germany) using a version 1.1 BigDye Terminator cycle
sequencing kit and a BigDye Xterminator purification kit
(Life Technologies, Foster City, USA).
Statistical analysis
Fisher’s exact test was used to examine associations be-
tween nominal variables. Student’s t test was used to
examine the association between nominal variables and
age. Significance was defined as p < 0.05.
Results
TERT promoter hotspot mutations in soft tissue sarcomas
TERT promoter mutations were detected in 36 of 341
sarcoma samples from 341 patients (10.5%; Table 1).
The mutations comprised 32 C228T mutations, but only
three C250T mutations. They occurred in a mutual ex-
clusive manner with a heterozygous genotype (Figure 1).
Mutations were highly recurrent (29/39; 74%) in myxoid
liposarcomas (MLS) and were almost exclusively found
at position C228T with the exception for one case with
a C250T mutation. Remarkably, the 28 MLS carrying a
C228T mutation were all positive for the FUS-DDIT3
fusion, while the C250T mutation was found in one
of two MLS with an EWSR1-DDIT3 fusion transcript
(Additional file 1: Table S2). Looking for associations be-
tween the TERT promoter mutation status and clinico-
pathological features of the MLS (Table 2), there were no
associations between TERT promoter mutational statusand phenotype (myxoid vs. round cell variant), tumor
grading, tumor site and patients’ median age or gender.
Solitary fibrous tumors (SFTs) showed TERT promoter
mutations in four cases (4/31; 13%), which were exclu-
sively located at position C228T. In addition, two malig-
nant peripheral nerve sheath tumors (MPNSTs) harbored
a TERT promoter mutation (2/35; 6%), one case with a
C228T and the other one with a C250T mutation. Finally,
a TERT promoter mutation at position C228T was found
in one of the synovial sarcomas (SSs) examined (1/25; 4%).
All other sarcoma types, which comprised 61 dedifferen-
tiated liposarcomas, 15 pleomorphic liposarcomas, 27 leio-
myosarcomas, 40 undifferentiated pleomorphic sarcomas,
17 myxofibrosarcomas, 9 low-grade fibromyxoid sarco-
mas, 10 dermatofibrosarcomata protuberans, 8 extraskele-
tal myxoid chondrosarcomas, 9 angiosarcomas, 6 alveolar
soft part sarcomas, 5 clear cell sarcomas, and 4 epithelioid
sarcomas had a wild type genotype at the two TERT pro-
moter hotspot loci (Table 1).
TERT promoter hotspot mutations in soft tissue sarcoma
cell lines
We also sequenced 16 sarcoma cell lines for the TERT
promoter hotspot mutations (Table 3). Mutations were
found in both MLS cell lines and in one of three
MPNST cell lines. Mutations were restricted to the
C228T locus. The genotype at the two hotspot positions
of the TERT promoter of the remaining cell lines, which
included two well-differentiated liposarcomas, one dedif-
ferentiated liposarcomas, one pleomorphic liposarcoma,
one liposarcoma not further subtyped, four SSs, and one
fibrosarcoma, was wild type.
Discussion
Telomere maintenance mechanisms represent a pivotal
cornerstone in the development and sustainment of can-
cer. The recently described mutations in the promoter
region of TERT provide new evidence for the important
role of telomerase reactivation in human cancers. The
overall prevalence of TERT promoter hotspot mutations
was low in the comprehensive series of soft tissue sarco-
mas examined in this study (36/341; 10.5%). However,
the prevalence strongly varied by sarcoma type.
The by far highest mutation rate was found in MLS
(29/39; 74%), which represents the most prevalent muta-
tion identified in this sarcoma entity to date, and which
corroborates data obtained in a recent study on a
smaller series of MLS [16]. In MLS, increased TERT
transcription [27-29] and telomerase reactivity [28] have
been described previously. Costa et al. found telomerase
reactivation in 69% of MLS with an additional round cell
component (high grade) [28], which is overlapping with
the overall TERT promoter mutation frequency of 74%
(29/39) in our series of MLS. However, in pure MLS
Table 1 Prevalence of TERT promoter hotspot mutations in soft tissue tumors
Diagnosis Mut (n) Total (n) Mut (%) C228T (n) C250T (n)
Myxoid liposarcoma 29 39 74% 28 1
Dedifferentiated liposarcoma 0 61
Pleomorphic liposarcoma 0 15
Leiomyosarcoma 0 27
Synovial sarcoma 1 25 4% 1
Malignant peripheral nerve sheath tumor 2 35 6% 1 1
Undifferentiated pleomorphic sarcoma 0 40
Myxofibrosarcoma 0 17
Low grade fibromyxoid sarcoma 0 9
Dermatofibrosarcoma protuberans 0 10
Solitary fibrous tumor 4 31 13% 4
Extraskeletal myxoid chondrosarcoma 0 8
Angiosarcoma 0 9
Alveolar soft part tumor 0 6
Clear cell sarcoma 0 5
Epithelioid sarcoma 0 4
36 341 33 3
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low grade), they found telomerase reactivation only in
39% of cases [28]. Likewise, Schneider-Stock et al. de-
tected telomerase activity in 30% of MLS, but elevated
TERT mRNA levels in a much higher proportion of
cases [27,29,30]. Furthermore, intratumoral heterogen-
eity of TERT expression and telomerase activity has
been observed in sarcomas, in particular in liposarco-
mas [31]. Thus, TERT mRNA levels are not stringently
correlated with telomerase enzyme activity. This mightFigure 1 Schematic figure of the TERT promoter region. Schematic figu
molecular position on chromosome 5, DNA sequence of the mutational ho
shows the nucleotide exchange of cytosine by thymine (depicted in red). E
complex factors (Ets/TCF) transcription factors (highlighted by greyish recta
C228T/C250T mutations (indicated by arrows).be explained by sufficient regulatory mechanisms of the
enzymatic function of telomerase, which still have to be
functional in some tumors.
Indeed, regulatory mechanisms of telomerase have
already been described at the transcriptional and post-
translational level. At the transcriptional level, alternative
splicing of TERTmRNA itself might not only lead to TERT
variants with impaired catalytic functions [32], but also to
a variant that acts in a dominant-negative manner on
telomerase activity [33]. Furthermore, post-translationalre of the TERT promoter region with nucleotide numbering of the
tspot region with a wild type strand and a mutated strand, which
ach mutation leads to a new binding motif for E-twenty six/ternary
ngles). Representative sequencing chromatograms show heterozygous
Table 2 Correlation between clinicopathological patient
characteristics and TERT promoter genotype in myxoid
liposarcomas
Mutant Wild-type P value
Phenotype (n = 39) 0.2125
Myxoid 23 6
Round cell 6 4




Localization (n = 39) 0.1958
Extremity 23 10
Other 5 0
Age (years) (n = 39) 0.6748
Mean ± SD 48 ± 3 50 ± 5
Median (range) 46 (16–84) 43 (36–74)
Gender (n = 39) 0.6395
Female 9 3
Male 20 7
Table 3 List of soft tissue sarcoma cell lines with the
corresponding TERT promoter mutation status

















Abbreviations: WDLS well differentiated liposarcoma, DDLS dedifferentiated
liposarcoma, MLS myxoid liposarcoma, SS synovial sarcoma, MPNST malignant
peripheral nerve sheath tumor, FS fibrosarcoma, LS liposarcoma, WT wild
type, C228T cytosine exchange to thymine at chromosome 5 base position
1,295,228.
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ation or ubiquitination have been shown to affect the
catalytic activity and stability of TERT [34].
Anyhow, our data suggest that mutation of the TERT
promoter causes telomerase reactivation in MLS and
thereby most probably provides unlimited proliferative
potential. This assumption is also underpinned by a re-
porter gene assay of the two most common mutation
variants within the promoter region of TERT, namely
C228T and C250T, which were shown to lead to an aug-
mented expression of TERT [12]. Further, the high
prevalence of TERT promoter mutations not only in
MLS round cell variants but also in MLS with a pure
myxoid phenotype, and this irrespective of tumor grading,
implies that these mutations act rather as driver than pas-
senger mutations.
TERT promoter mutations might also have a diagnos-
tic impact in myxoid sarcomas. Mutations were found
neither in dedifferentiated liposarcomasa (DDLS), nor in
pleomorphic liposarcomas (PLS), which presented myx-
oid areas in many cases, and were also not detectable in
our series of myxofibrosarcomas, extraskeletal myxoid
chondrosarcomas, dermatofibrosarcomata protuberans,
and low-grade fibromyxoid sarcomas.
The absence of TERT promoter hotspot mutations in
our series of DDLS and PLS is in line with previous
studies, which largely observed deficient telomerase ac-
tivity in high-grade liposarcomas. Instead, high-grade
liposarcomas often use the ALT mechanism [28,35,36].
ALT overcomes telomere attrition through homologous
recombination of telomeric DNA and characteristically
presents with a pattern of telomere lengths that range
from very short to abnormally long. This telomere pat-
tern is clearly different compared to tumors with tel-
omerase reactivation, where telomere length is found
almost equal [36].It has been shown that ALT-positive
liposarcomas have a notably worse outcome, and may
imply a more favorable prognosis for TERT promoter
mutated liposarcomas [28,37,38]. However, differences
in patients outcome might be dedicated to the fact that
telomere maintenance via ALT is more often applied by
tumors with complex karyotypes or with a higher level
of genomic instability [39,40], whereas sarcomas charac-
terized by type specific translocations rather use tel-
omerase reactivation for telomere maintenance [39,41].
According to our data, this concept holds true for the
group of liposarcomas. MLS are characterized by a
translocation that fuses the DDIT3 (CHOP) gene on
chromosome 12q13 with the FUS (TLS) gene on chromo-
some 16p11 in approximately 90% of cases, or the DDIT3
(CHOP) with the EWSR1 on chromosome 22q12 in the
remaining cases [42]. By contrast, DDLS typically have
complex karyotypic aberrations with amplification of the
chromosome 12 subregion q13-15, which includes the
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kinase-4 (CDK4) genes among others [43,44]. PLS are
characterized by highly complex karyotypes [45]. The high-
est prevalence of ALT has been observed in DDLS and
PLS, which typically have an aggressive biological behavior
[28,37]. However, TERT promoter mutated MLS may
undergo malignant progression to the round cell variant
and then present with a similar biological behavior like
ALT-positive PLS [46]. Another fact that challenges this
concept is that patients suffering from ALT-positive glio-
blastoma have a more favorable clinical course compared
to ALT-negative counterparts [47,48]. Thus, the unfavor-
able prognosis in ALT-positive liposarcomas is probably
derived from the mutational signature in these tumors
rather than dependent on the mechanism of telomere
maintenance, and thus may considerably differ between
different tumor entities.
The second most common rate of TERT promoter
mutations was observed in SFT with a frequency of 13%,
which is concordant to data on a smaller series of
SFTs [16]. However, TERT promoter mutation might
be dependent on the anatomic site of presentation, since
cranial SFTs and hemangiopericytomas, which are now
considered to belong to the SFT family from a genetic per-
spective [49], have a slightly higher mutation frequency
(11/43; 26%) [17].
In MPNSTs, TERT promoter mutations were found in
a small fraction of tumors (2/35; 6%), which is slightly
below the mutation frequency previously reported (2/12;
17%) [17]. These data might suggest a minor significance
in this tumor entity. On the other hand, one out of three
MPNST cell lines was revealed with a TERT promoter
mutation, which supports the assumption that telomer-
ase reactivation by TERT promoter mutations might
contribute to immortalization of at least a small propor-
tion of MPNSTs. Interestingly, a previous study that fo-
cused on telomerase activity in MPNSTs found telomerase
reactivation in 14 of 23 (61%) MPNSTs [50]. Compared
with histological grade, telomerase activity was completely
restricted to high grade MPNSTs (14/17; 82%) in that
study. Indeed, the two MPNSTs with TERT promoter mu-
tation described here presented with typical histological
features of high-grade MPNSTs [51]. Moreover, in another
study on 57 MPNST samples telomerase activity proved to
be significantly associated with disease-specific mortality
during 5 years of follow-up [52].
Another notable observation is the sporadic occur-
rence of TERT promoter mutations in SSs. This tumor
typically applies telomerase reactivation for telomere
maintenance [53], which is in concordance with our
own observations (data not shown). However, like in
MPNSTs, TERT promoter hotspot mutations just play a
minor role in SSs with merely a single mutated case in
our series (1/25; 4%). Thus, the low mutation frequenciesin MPNSTs and SSs suggest that a so far unknown mech-
anism beside the TERT promoter hotspot mutations may
exist that provides telomerase reactivation.
Explanations for telomerase maintenance get compli-
cated by the observation that a considerable fraction of
STS do neither apply telomerase activation nor the ALT
mechanism that is so far known, or even may be
equipped with both mechanisms [7,36]. Further studies
concerning molecular alterations in STS will in particular
draw more attention to the non-coding genomic regions
and hopefully elucidate the remaining unanswered ques-
tions, which mechanisms these tumors exploit to prevent
telomere attrition.
Conclusion
We determined the prevalence of TERT promoter hotspot
mutations in STS. Despite the overall low prevalence in
this tumor group, TERT promoter mutations revealed to
be a highly recurrent event in MLS and currently represent
the most prevalent mutation identified in this sarcoma en-
tity (74%). Forthcoming studies will be needed to deter-
mine whether the TERT promoter mutational status could
be of clinical relevance, especially in advanced MLS. Add-
itionally, TERT promoter mutations were also found in a
subset of SFTs (13%), and in a number of MPNSTs (6%)
and SSs (4%). Given the relative frequency of telomerase
activation reported in MPNSTs and in SSs, the low TERT
promoter mutation rate in these sarcoma types implies that
a so far unknown mechanism, different from the presently
known TERT promoter hotspot mutations, provides tel-
omerase reactivation in these sarcoma entities.Additional file
Additional file 1: Table S1. Clinicopathological patients’ characteristics.
Internal identifier, diagnosis, patients’ age at surgery, gender, tumor
localization, presence/absence of a fusion transcript, and TERT
promoter mutational status with nucleotide exchange, are indicated
for all cases. Abbreviations: UPS = undifferentiated pleomorphic sarcoma;
DDLS = dedifferentiated liposarcoma; PLS = pleomorphic liposarcoma;
MLS =myxoid liposarcoma; LMS = leiomyosarcoma; SS = synovial sarcoma;
MFS = myxofibrosarcoma; MPNST = malignant nerve sheath tumor;
EMCS = extraskeletal myxoid chondrosarcoma; SFT = solitary fibrous tumors;
ASPS = alveolar soft part sarcoma; CCS = clear cell sarcoma; EPS = epithelioid
sarcoma; DFSP = dermatofibrosarcoma protuberans; LGFMS = low-grade
fibromyxoid sarcoma; AS = angiosarcoma. Additional file 1: Table S2.
Molecular and histological features of the myxoid liposarcomas. Internal
identifier, patients’ age at surgery, gender, tumor localization, and TERT
promoter mutational status with nucleotide exchange together with
information about the histological phenotype, tumor grading and
presence/absence of gene fusions (FUS-DDIT3; EWSR1-DDIT3) are
given for myxoid liposarcomas. Abbreviations: MLS =myxoid liposarcoma;
MYX =myxoid; RC = round cell; wt = wild type; mut =mutated; DDIT3
split = FISH probe indicates interrupted gene; na = not available; nd = not
determinable. Additional file 1: Table S3. Soft tissue sarcoma cell lines.
Cell line name, tissue of origin (soft tissue sarcoma subtype), molecular
confirmation, culture conditions and source/reference is given for each
cell line tested for TERT promoter mutations. Abbreviations: FCS = fetal calf
serum; PS = penicillin and streptomycin; PMID = PubMed identifier.
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